-
Sorainen publishes Sustainability Report 2024
We have released this year’s edition of our third annual Sustainability Report, outlining the efforts made by Sorainen during the year 2023. “These efforts are not just about compliance but about making a real difference for our people, communities and region,” Managing Partner Eva Berlaus noted in the report’s opening comments. She noted that the […]
-
Sorainen earns two nominations from The Financial Times
Sorainen counsel Lise-Lotte Lääne has been shortlisted for the prestigious “Innovative Lawyers in Deals and Financing” award. As a firm, Sorainen has been nominated for the “Most Innovative Law Firm in Europe (HQ outside the UK)” award. The Financial Times Awards recognise law firms and in-house teams that excel in digital innovation and employ creative […]
-
Clients: Sorainen’s legal competence is the best in the market
According to the 2024 Baltic Kantar Prospera client survey of top-tier Baltic law firms, Sorainen ranks first in the “Best legal competence” category, as it has done for the past three years. Sorainen Estonia ranked as #1 law firm in Estonia according to overall rankings. Strongest legal fields according to clients Sorainen placed first in […]
-
Sorainen receives gold label from the Responsible Business Forum
We are pleased to announce that we have received the gold-level quality label from the Estonian Responsible Business Forum (VEF). This award recognises our efforts to promote responsible entrepreneurship in Estonia. Responsible entrepreneurship involves the seamless and voluntary integration of economic, environmental and social dimensions into a company’s daily activities, management and business strategy. “We […]
-
Spreading misleading information about competing drugs can be an infringement of competition law
On 22 July 2024, the European Commission (EC) announced that it will be imposing certain commitments on Vifor, a manufacturer of intravenous iron medicines. Vifor is a dominant player in this market and had spread misleading information about the safety of a competing drug, Monofer, to healthcare professionals. The EC had opened an investigation, suspecting a potential […]